Community Health Media

@UCCB0N8VIIexXP10t_HDabQA - 81 subscribers

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts Learn more about us here - communityhealth.media

Home Videos Live Playlists

DESTINY-Breast09 & the Future of Care - Dr. Irene Kang & Dr. Aditya Bardia

DESTINY-Breast09 & the Future of Care - Dr. Irene Kang & Dr. Aditya Bardia Community Health Media

2.3K views - 3 weeks ago

Introducing The Breast Friends Podcast | Where Breast Cancer Science Meets Real Talk

Introducing The Breast Friends Podcast | Where Breast Cancer Science Meets Real Talk Community Health Media

178 views - 1 month ago

Can T-DXd Change Early HER2+ Breast Cancer Forever? - Dr. Ruta Rao & Dr. VK Gadi

Can T-DXd Change Early HER2+ Breast Cancer Forever? - Dr. Ruta Rao & Dr. VK Gadi Community Health Media

83 views - 1 month ago

Induction to Maintenance: Is This the Future of ADCs in 1st line HER2+ mBC?

Induction to Maintenance: Is This the Future of ADCs in 1st line HER2+ mBC? Community Health Media

22 views - 1 month ago

What Comes After DESTINY-Breast09?

What Comes After DESTINY-Breast09? Community Health Media

26 views - 1 month ago

Monitoring ILD with T-DXd: What Clinicians Need to Know

Monitoring ILD with T-DXd: What Clinicians Need to Know Community Health Media

2.8K views - 1 month ago

Dose Optimization: The Secret to Long-Term T-DXd Success

Dose Optimization: The Secret to Long-Term T-DXd Success Community Health Media

15 views - 1 month ago

Managing Risk vs Benefit with T-DXd

Managing Risk vs Benefit with T-DXd Community Health Media

2.5K views - 1 month ago

Who Should Receive T-DXd First Line?

Who Should Receive T-DXd First Line? Community Health Media

8 views - 1 month ago

DESTINY-Breast09: Nearly 4 Years of PFS with T-DXd

DESTINY-Breast09: Nearly 4 Years of PFS with T-DXd Community Health Media

2.4K views - 1 month ago

Why First-Line Therapy Matters in HER2+ Metastatic Breast Cancer

Why First-Line Therapy Matters in HER2+ Metastatic Breast Cancer Community Health Media

19 views - 1 month ago

Why the Curative Setting Changes the Risk–Benefit Equation

Why the Curative Setting Changes the Risk–Benefit Equation Community Health Media

5 views - 1 month ago

Managing ILD Risk & Radiation With Adjuvant T-DXd

Managing ILD Risk & Radiation With Adjuvant T-DXd Community Health Media

7 views - 1 month ago

DESTINY-Breast05 Explained: Can We Beat T-DM1?

DESTINY-Breast05 Explained: Can We Beat T-DM1? Community Health Media

11 views - 1 month ago

Adaptive Neoadjuvant Therapy: Are We Ready Yet?

Adaptive Neoadjuvant Therapy: Are We Ready Yet? Community Health Media

7 views - 1 month ago

Residual Disease After Neoadjuvant Therapy: What Comes Next?

Residual Disease After Neoadjuvant Therapy: What Comes Next? Community Health Media

8 views - 1 month ago

Is Anthracycline-Free Neoadjuvant Therapy Finally Here?

Is Anthracycline-Free Neoadjuvant Therapy Finally Here? Community Health Media

5 views - 1 month ago

83% pCR: DESTINY-Breast11 Breaks the Neoadjuvant Ceiling

83% pCR: DESTINY-Breast11 Breaks the Neoadjuvant Ceiling Community Health Media

10 views - 1 month ago

Should T-DXd Move Upfront in Early-Stage HER2+ Breast Cancer?

Should T-DXd Move Upfront in Early-Stage HER2+ Breast Cancer? Community Health Media

6 views - 1 month ago

Why HER2 Status Alone Is No Longer Enough

Why HER2 Status Alone Is No Longer Enough Community Health Media

3 views - 1 month ago

What Happens After T-DXd? Sequencing Without a Playbook

What Happens After T-DXd? Sequencing Without a Playbook Community Health Media

3 views - 1 month ago

What Comes After T-DXd in HER2+ Metastatic Breast Cancer?

What Comes After T-DXd in HER2+ Metastatic Breast Cancer? Community Health Media

8 views - 1 month ago

Managing ILD With T-DXd: What Clinicians Need to Know

Managing ILD With T-DXd: What Clinicians Need to Know Community Health Media

6 views - 1 month ago

Choosing First-Line Therapy in HER2+ Metastatic Disease

Choosing First-Line Therapy in HER2+ Metastatic Disease Community Health Media

6 views - 1 month ago

The Frontline Face-Off: DB-09, PATINA, and HER2CLIMB-05

The Frontline Face-Off: DB-09, PATINA, and HER2CLIMB-05 Community Health Media

15 views - 1 month ago

DESTINY-Breast09 Explained: Why 40 Months PFS Matters

DESTINY-Breast09 Explained: Why 40 Months PFS Matters Community Health Media

1 views - 1 month ago

Redefining the Horizon: Is Cure Possible in HER2+ mBC?

Redefining the Horizon: Is Cure Possible in HER2+ mBC? Community Health Media

3 views - 1 month ago

HER2+ Breast Cancer: The Most Transformed Disease in Oncology?

HER2+ Breast Cancer: The Most Transformed Disease in Oncology? Community Health Media

11 views - 1 month ago

Eliminating the Surprise: Mapping the Path for Adjuvant Therapy After Surgery

Eliminating the Surprise: Mapping the Path for Adjuvant Therapy After Surgery Community Health Media

8 views - 1 month ago

Is pCR Enough? Why Regulators Still Want EFS Data

Is pCR Enough? Why Regulators Still Want EFS Data Community Health Media

5 views - 1 month ago

“Best Drug on Earth” Isn’t Enough If Patients Can’t Tolerate It

“Best Drug on Earth” Isn’t Enough If Patients Can’t Tolerate It Community Health Media

12 views - 1 month ago

Does Higher pCR Come at a Cost? Weighing Efficacy vs Toxicity in DB-11

Does Higher pCR Come at a Cost? Weighing Efficacy vs Toxicity in DB-11 Community Health Media

4 views - 1 month ago

Beyond KATHERINE: The DB-05 Shift in High-Risk HER2+ Disease

Beyond KATHERINE: The DB-05 Shift in High-Risk HER2+ Disease Community Health Media

11 views - 1 month ago

The New 1st Line Reality in HER2+ mBC: Why the Strongest Tool Goes First

The New 1st Line Reality in HER2+ mBC: Why the Strongest Tool Goes First Community Health Media

7 views - 1 month ago

PATINA, HER2CLIMB-05 & the Maintenance Therapy Debate

PATINA, HER2CLIMB-05 & the Maintenance Therapy Debate Community Health Media

9 views - 1 month ago

Vigilance is Key: Managing ILD with T-DXd

Vigilance is Key: Managing ILD with T-DXd Community Health Media

1 views - 1 month ago

The 1st Line Decision: Why T-DXd is Redefining the Start

The 1st Line Decision: Why T-DXd is Redefining the Start Community Health Media

4 views - 1 month ago

Beyond CLEOPATRA: When the 1L Standard Falls Short

Beyond CLEOPATRA: When the 1L Standard Falls Short Community Health Media

1 month ago

Cleopatra’s Survival Impact in HER2+ Metastatic Breast Cancer

Cleopatra’s Survival Impact in HER2+ Metastatic Breast Cancer Community Health Media

5 views - 1 month ago

Induction, Maintenance, or Both? Rethinking HER2+ mBC Treatment Strategy

Induction, Maintenance, or Both? Rethinking HER2+ mBC Treatment Strategy Community Health Media

6 views - 1 month ago

The T-DXd Tradeoff: Balancing Breakthrough Efficacy with ILD Risk

The T-DXd Tradeoff: Balancing Breakthrough Efficacy with ILD Risk Community Health Media

2 views - 1 month ago

Years on First-Line Therapy: A New Reality for Metastatic Breast Cancer

Years on First-Line Therapy: A New Reality for Metastatic Breast Cancer Community Health Media

10 views - 1 month ago

40-Month PFS: Why Destiny-Breast09 Is a Game Changer

40-Month PFS: Why Destiny-Breast09 Is a Game Changer Community Health Media

3 views - 1 month ago

Is It Time to Move Beyond Cleopatra in HER2+ Metastatic Breast Cancer?

Is It Time to Move Beyond Cleopatra in HER2+ Metastatic Breast Cancer? Community Health Media

3 views - 1 month ago

After Frontline T-DXd: How Should HER2+ Disease Be Sequenced Next?

After Frontline T-DXd: How Should HER2+ Disease Be Sequenced Next? Community Health Media

5 views - 1 month ago

Maintenance or Maximum Response? Rethinking Long-Term Control in HER2+ Disease

Maintenance or Maximum Response? Rethinking Long-Term Control in HER2+ Disease Community Health Media

3 views - 1 month ago

Supportive Care with T-DXd: Antiemetics, Fatigue & Hair Preservation

Supportive Care with T-DXd: Antiemetics, Fatigue & Hair Preservation Community Health Media

2 views - 1 month ago

Which HER2+ Patients Should Receive T-DXd + Pertuzumab First-Line?

Which HER2+ Patients Should Receive T-DXd + Pertuzumab First-Line? Community Health Media

2 views - 1 month ago

Managing T-DXd Toxicity: ILD, Nausea, Fatigue & What to Watch For

Managing T-DXd Toxicity: ILD, Nausea, Fatigue & What to Watch For Community Health Media

2 views - 1 month ago

Frontline HER2+ Therapy: Why “Best Drug First” May Matter More Than Sequencing

Frontline HER2+ Therapy: Why “Best Drug First” May Matter More Than Sequencing Community Health Media

3 views - 1 month ago

DESTINY-Breast09: 40-Month PFS — A New First-Line Reality for HER2+ Disease?

DESTINY-Breast09: 40-Month PFS — A New First-Line Reality for HER2+ Disease? Community Health Media

6 views - 1 month ago

CLEOPATRA Explained: How It Became the First-Line Standard in HER2+ Breast Cancer

CLEOPATRA Explained: How It Became the First-Line Standard in HER2+ Breast Cancer Community Health Media

15 views - 1 month ago

Dare We Say “Cure” in HER2 + Metastatic Breast Cancer?

Dare We Say “Cure” in HER2 + Metastatic Breast Cancer? Community Health Media

11 views - 1 month ago

Treating to Progression vs. Clinical Flexibility: Finding the Balance

Treating to Progression vs. Clinical Flexibility: Finding the Balance Community Health Media

2 views - 1 month ago

Is T-DXd Worth the Risk? Evaluating Benefit vs Toxicity

Is T-DXd Worth the Risk? Evaluating Benefit vs Toxicity Community Health Media

2 views - 1 month ago

Who Should Receive T-DXd + Pertuzumab in the First Line?

Who Should Receive T-DXd + Pertuzumab in the First Line? Community Health Media

3 views - 1 month ago

DESTINY-Breast09: 40 Months of PFS Changes Everything

DESTINY-Breast09: 40 Months of PFS Changes Everything Community Health Media

6 views - 1 month ago

Why CLEOPATRA Became the Gold Standard in HER2+ Metastatic Breast Cancer

Why CLEOPATRA Became the Gold Standard in HER2+ Metastatic Breast Cancer Community Health Media

5 views - 1 month ago

Why Waiting for Second Line May Cost Patients Everything

Why Waiting for Second Line May Cost Patients Everything Community Health Media

20 views - 1 month ago

PATINA & HER2CLIMB-05: Rethinking Maintenance Therapy

PATINA & HER2CLIMB-05: Rethinking Maintenance Therapy Community Health Media

5 views - 1 month ago